iRhythm Technologies

Valuation Analysis

About the Company

iRhythm Technologies en bref

iRhythm Technologies (IRTC) is currently trading at 101,82 € with a market capitalization of 3,3 Md €. The 52-week range spans from 87,64 € to 184,24 €; the current price is 44.7% below the yearly high. Year-over-year revenue growth stands at +25.7%.

💰 Dividende

iRhythm Technologies currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

14 analystes évaluent iRhythm Technologies (IRTC) au consensus : Achat Fort. L'objectif de cours moyen est de 153,88 €, soit un potentiel de +51.12% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 130,36 € à 221,60 €.

iRhythm Technologies : la thèse d'investissement en détail

iRhythm Technologies (IRTC) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Top-line momentum is unusually strong with revenue expanding 25.7% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. With a gross margin near 71%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Strong Buy with an average price target implying roughly 51.12% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. The debt-to-equity ratio of 452.39% is elevated, meaning the company relies heavily on creditors — refinancing terms will become more important than operational performance in the next economic downturn. Short interest sits at 10.54% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

À surveiller

• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 51.12% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to market-like volatility, elevated short interest (10.54%), higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy iRhythm Technologies?

Compare top-rated brokers — low fees, trusted providers, fully regulated.